UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16a OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January, 2002
ALTAREX CORP.
(Exact name of Registrant as specified in its charter)
610 LINCOLN STREET
WALTHAM, MA, USA 02451
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
-------- -------
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
------- -------
On January 24, 2002, AltaRex Corp. (the "Company") announced clinical results
from a primary analysis of its OvaRex(R) combined United States and Canadian
phase IIb trial in metastatic late stage ovarian cancer. The full text of the
press release issued in connection with the announcement is filed as Exhibit
99.1 to this Current Report on Form 6-K and is incorporated herein by reference.
INDEX TO EXHIBITS
EXHIBIT NO. DESCRIPTION
- ----------- -----------
99.1 Press Release Regarding OvaRex(R) Phase IIb Results, dated
January 24, 2002.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ALTAREX CORP.
By: /s/ Edward M. Fitzgerald
--------------------------------------------
Name: Edward M. Fitzgerald
Title: Senior Vice President and
Chief Financial Officer
Date: January 29, 2002
-2-